MMP9 and cancer: The rational for the use of AMD3100 in oncology is that CXCR4 binding by natural ligands, such as the CXCL12 chemokine, triggers PI3K/AKT, thereby promoting MMP-9 expression [223] and cancer cell invasion/dissemination [224,225,226,227,228].